



**Contacts:**

Matt Niloff  
Senior Product Director  
Xcellerex, Inc.  
508-683-2296

**Parrish Galliher to Speak  
at 6<sup>th</sup> Annual Biodefense Vaccines  
& Therapeutics Conference**

*Conference and Symposium to be held  
June 9-11 in Washington, DC*

**Marlborough, MA, April 10, 2008** – Xcellerex, Inc. announced today that Parrish Galliher, the company's founder and Chief Technology Officer, will be a featured speaker at the 6th Annual **Biodefense Vaccines and Therapeutics Conference** on Monday, June 9, 2008.

The presentation will detail how Xcellerex's disposables-based bioreactors and breakthrough FlexFactory™ biomanufacturing platform deliver unique advantages in flexibility and speed-of-deployment when applied in rapid response vaccine and biotherapeutics manufacturing.

The conference will be held at the Almas Temple Club in Washington, DC and will feature a select group of speakers from the government and private sector. A link with additional conference information can be found on the Xcellerex Events page:

<http://www.xcellerex.com/news-xcellerex-events.htm>

**- more-**

### **About Xcellerex, Inc.**

Xcellerex is built around a unique biomanufacturing platform that features the innovative application of single-use component technology. Xcellerex offers a suite of world-class products and services to support the adoption of its platform. These include the XDR line of GMP single-use bioreactors, PDMax™ high-throughput process development and optimization services, and proven GMP manufacturing operated by an experienced CMC team. The company also actively seeks creative partnerships to facilitate access to the platform. Learn more at [www.xcellerex.com](http://www.xcellerex.com)

### **About the Conference**

The U.S. federal government is strongly committed to building a robust biodefense and pandemic influenza industry with the capabilities and the capacity to meet the nation's urgent needs. Federal agencies have a continued focus of accelerating the research and advanced development of novel vaccines, therapeutics and other medical countermeasures. The government is striving to help companies transition their products from development to procurement for the Strategic National Stockpile (SNS) with a number of programs and initiatives including Project Bioshield and the Pandemic Influenza Preparedness Program.

For members of industry looking to participate in these and other biodefense and pandemic related efforts, the Biodefense Vaccines and Therapeutics conference is the ideal venue to learn the latest and most detailed information on current research and development countermeasure programs, as well as interact face-to-face with high-level government representatives tasked with building the country's biodefense and pandemic influenza capacity. As in previous years, the conference will provide the private sector with detailed information on participation in addressing the nation's needs for medical countermeasures.

The event will feature high-level speakers from the government and private sector.

## **XCELLEREX SPEAKER BIOGRAPHY**

### **Parrish Galliher**

#### **Founder and Chief Technology Officer**

Mr. Galliher earned his BA in Biology at Boston University (1975). After 3 years as an EIT at Dynatech R/D Corp., he began graduate studies at MIT and earned his MS in Biochemical Engineering. Mr. Galliher joined Biogen, Inc. in 1981 where he was responsible for design, commissioning and management of Biogen's first biomanufacturing facility. He held various management positions in Process Development, Engineering and Clinical Manufacturing of biopharmaceuticals using bacteria, yeast and mammalian cells. As Director of Process Engineering, he led the team responsible for startup, initial validation and commissioning of Biogen's Avonex manufacturing facility licensed by the FDA in 1996. Mr. Galliher joined Alpha-Beta Technology (ABT) in January of 1994 as Director of Manufacturing Development and was promoted to Vice President in 1995. He led the team responsible for technology transfer, startup, validation, and commissioning of ABT's biopharmaceutical manufacturing plant in Smithfield, RI, and was appointed Vice President of Operations and General Manager in 1997. Mr. Galliher joined LeukoSite, Inc. in 1999 as Vice President of Biologics Manufacturing. After Millennium Pharmaceuticals acquired LeukoSite later that year, Mr. Galliher managed Millennium's worldwide biologics manufacturing operations, including leadership of the CMC Team that contributed to FDA licensure of the CAMPATH monoclonal antibody in 2001. He also led the Manufacturing Productivity Improvement program, which

enabled high speed development of Millennium's anti-CCR-2 Mab for clinical trials.  
Mr. Galliher founded Xcellerex in December 2002.

###